Jonathan Wolleben
Stock Analyst at JMP Securities
(4.47)
# 429
Out of 4,641 analysts
167
Total ratings
51.88%
Success rate
20.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Reiterates: Market Outperform | $9 | $3.46 | +160.12% | 7 | Oct 1, 2024 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Market Outperform | $80 | $59.61 | +34.21% | 12 | Sep 27, 2024 | |
| ALLK Allakos | Reiterates: Market Outperform | $3 | $1.34 | +123.88% | 6 | Sep 26, 2024 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $5 | $0.70 | +614.29% | 10 | Sep 24, 2024 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Market Outperform | $64 | $49.13 | +30.27% | 1 | Sep 17, 2024 | |
| AURA Aura Biosciences | Maintains: Market Outperform | $19 → $23 | $11.39 | +101.93% | 6 | Sep 13, 2024 | |
| SKYE Skye Bioscience | Initiates: Market Outperform | $15 | $4.94 | +203.64% | 1 | Sep 10, 2024 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $48 → $32 | $5.90 | +442.37% | 8 | Aug 15, 2024 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $91 → $86 | $39.41 | +118.22% | 6 | Aug 9, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $45 → $43 | $46.44 | -7.41% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $16 | $7.95 | +101.26% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $381 → $385 | $203.59 | +89.11% | 10 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $66 → $68 | $39.68 | +71.37% | 8 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $7.53 | +232.01% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $24 | $6.80 | +252.94% | 10 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $22 | $11.30 | +94.69% | 16 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.08 | +640.74% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $49 → $50 | $22.36 | +123.61% | 9 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $3 | $0.56 | +439.57% | 6 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $1.19 | +321.94% | 9 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.78 | +58.73% | 6 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $31.80 | -24.53% | 1 | May 12, 2023 |
Savara
Oct 1, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.46
Upside: +160.12%
Crinetics Pharmaceuticals
Sep 27, 2024
Reiterates: Market Outperform
Price Target: $80
Current: $59.61
Upside: +34.21%
Allakos
Sep 26, 2024
Reiterates: Market Outperform
Price Target: $3
Current: $1.34
Upside: +123.88%
DBV Technologies
Sep 24, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.70
Upside: +614.29%
Rhythm Pharmaceuticals
Sep 17, 2024
Initiates: Market Outperform
Price Target: $64
Current: $49.13
Upside: +30.27%
Aura Biosciences
Sep 13, 2024
Maintains: Market Outperform
Price Target: $19 → $23
Current: $11.39
Upside: +101.93%
Skye Bioscience
Sep 10, 2024
Initiates: Market Outperform
Price Target: $15
Current: $4.94
Upside: +203.64%
Sagimet Biosciences
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $5.90
Upside: +442.37%
Structure Therapeutics
Aug 9, 2024
Maintains: Market Outperform
Price Target: $91 → $86
Current: $39.41
Upside: +118.22%
Protagonist Therapeutics
Aug 7, 2024
Maintains: Market Outperform
Price Target: $45 → $43
Current: $46.44
Upside: -7.41%
Aug 6, 2024
Maintains: Market Outperform
Price Target: $15 → $16
Current: $7.95
Upside: +101.26%
Jul 16, 2024
Maintains: Market Outperform
Price Target: $381 → $385
Current: $203.59
Upside: +89.11%
Jun 18, 2024
Maintains: Market Outperform
Price Target: $66 → $68
Current: $39.68
Upside: +71.37%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $7.53
Upside: +232.01%
May 10, 2024
Maintains: Market Outperform
Price Target: $25 → $24
Current: $6.80
Upside: +252.94%
May 8, 2024
Maintains: Market Outperform
Price Target: $24 → $22
Current: $11.30
Upside: +94.69%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $1.08
Upside: +640.74%
Apr 11, 2024
Maintains: Market Outperform
Price Target: $49 → $50
Current: $22.36
Upside: +123.61%
Mar 14, 2024
Maintains: Market Outperform
Price Target: $8 → $3
Current: $0.56
Upside: +439.57%
Mar 13, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.19
Upside: +321.94%
May 17, 2023
Reiterates: Market Outperform
Price Target: $6
Current: $3.78
Upside: +58.73%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $31.80
Upside: -24.53%